Alexei Tumanov | Immunology | Innovative Research Award

Published on by Molecular Biologist

Innovative Research Award

Alexei Tumanov
The University of Texas at San Antonio, United States

Alexei Tumanov
Affiliation The University of Texas at San Antonio
Country United States
Google Scholar ID EDMA9agAAAAJ
Documents 97
Citations 7,514
h-index 41
Subject Area Immunology
Event International Molecular Biologist Awards
ORCID 0000-0001-6042-0152
Scopus 35351917100

Alexei Tumanov is an immunology researcher affiliated with the University of Texas at San Antonio and the Department of Microbiology, Immunology and Molecular Genetics at UT Health San Antonio. Institutional and bibliographic sources describe his research in relation to cytokine signaling, lymphotoxin biology, immune regulation, lymphoid-organ biology, inflammation, cancer immunotherapy and neuroimmune mechanisms.[1][2]

Abstract

Alexei Tumanov’s research profile is centered on molecular and cellular immunology, with particular emphasis on lymphotoxin signaling and its relationship to immune-system organization, inflammatory responses and disease mechanisms. His institutional research record includes investigations of lymphotoxin-beta receptor signaling, innate and adaptive immune responses, cancer immunotherapy and neuroimmune interactions.[1] Recent publications have examined lymphotoxin-beta receptor regulation of chronic pain, ferroptosis-associated regulation of innate lymphoid cell responses, and strategies intended to separate antitumor activity from immune-mediated toxicity in CD137-directed cancer immunotherapy.[2][3]

Keywords

  • Immunology
  • Molecular Immunology
  • Lymphotoxin Signaling
  • Lymphotoxin-beta Receptor
  • Cytokine Biology
  • Innate Immunity
  • Cancer Immunotherapy
  • Neuroimmune Regulation
  • Inflammation

Introduction

Molecular immunology examines how signaling pathways, immune-cell interactions and tissue environments regulate protective immunity and inflammatory disease. Within this field, lymphotoxin signaling represents an important area for studying the organization and maintenance of lymphoid tissues and the communication between immune and non-immune cells. Tumanov’s research has addressed these mechanisms through experimental studies of lymphotoxin pathways and their roles in immune-system development and disease-related processes.[1]

His earlier work included conditional targeting studies of lymphotoxin pathways in lymphoid organs. Such research contributed to the characterization of cell-specific functions of lymphotoxin and lymphotoxin-beta receptor signaling in peripheral lymphoid-organ development and maintenance.[4] More recent work has extended this research framework to inflammatory bowel disease, cancer immunotherapy and neuroimmune signaling.[2][3]

Research Profile

Institutional information identifies Tumanov as a researcher in the Department of Microbiology, Immunology and Molecular Genetics at UT Health San Antonio. His documented research interests include immune regulation, cytokine signaling and lymphotoxin biology. His research profile also encompasses interactions between immune pathways and pathological processes, including inflammation, cancer and chronic pain.[1][2]

The research program has included both fundamental and disease-oriented investigations. Earlier studies examined lymphotoxin-dependent organization of lymphoid organs, while later studies have investigated how related signaling mechanisms can influence therapeutic toxicity, inflammatory responses and sensory-neural processes.[4][5]

Research Contributions

A central contribution of Tumanov’s research is the investigation of lymphotoxin-beta receptor signaling as a regulator of immune and tissue processes. Experimental work has examined how this receptor pathway contributes to lymphoid-organ development and maintenance and how alterations in the pathway can affect inflammatory and pathological responses.[4]

In cancer immunotherapy, Tumanov has investigated mechanisms associated with the toxicity of CD137-directed treatment. A Cancer Prevention and Research Institute of Texas grant lists him as principal investigator for a project examining the role of lymphotoxin-beta receptor signaling in overcoming liver toxicity associated with anti-CD137 cancer immunotherapy.[5]

His recent collaborative research has also examined neuroimmune mechanisms. A 2026 Cell Reports publication reported that lymphotoxin-beta receptor signaling is involved in the development of chronic pain, providing experimental evidence connecting an immune signaling pathway with sensory processes.[3]

Additional work published in Cellular & Molecular Immunology examined ferroptosis in relation to ILC2 responses in inflammatory bowel disease. The article identifies lymphotoxin-related immunological research within a broader investigation of inflammatory mechanisms affecting innate lymphoid cells.[2]

Publications

Tumanov’s publication record spans molecular immunology, cytokine signaling, lymphoid-organ biology, inflammatory disease, cancer immunotherapy and neuroimmune regulation. His institutional profile lists publications including recent studies in Science Advances, Cell Reports and Cellular & Molecular Immunology.[1]

  • Tumanov, A. V., et al. (2026). Lymphotoxin-beta receptor controls the development of chronic pain. Cell Reports, 45(4), 117269. DOI: 10.1016/j.celrep.2026.117269.[3]
  • Korchagina, A. A., & Tumanov, A. V. (2026). Ferroptosis shapes ILC2 responses in inflammatory bowel disease. Cellular & Molecular Immunology, 23, 583–585. DOI: 10.1038/s41423-026-01404-z.[2]
  • Shein, S. A., Korchagina, A. A., Wang, L.-J., et al., including Tumanov, A. V. (2026). Selective elimination of circulating effector CD8 T cells via LTβR blockade separates anti-CD137 efficacy from toxicity. Science Advances, 12(17), eaea8737.[1]
  • Tumanov, A. V., et al. (2003). Dissecting the role of lymphotoxin in lymphoid organs by conditional targeting. Immunological Reviews. DOI: 10.1034/j.1600-065X.2003.00071.x.[4]

Research Impact

The documented research program connects fundamental immunological mechanisms with disease-oriented questions. Institutional records describe grant-supported research into the regulation of cancer immunotherapy toxicity and the role of lymphotoxin-beta receptor signaling in sensory neurons, while recent publications extend the research into chronic pain and inflammatory bowel disease.[2][3][5]

The quantitative metrics supplied for this recognition profile list 97 documents, 7,514 citations and an h-index of 41. Such metrics are bibliographic indicators and should be interpreted according to the database, date of retrieval and author-profile methodology used. The supplied Google Scholar, ORCID and Scopus identifiers provide external routes for verification and updating of these records.

The translational relevance of the research is also reflected in grant-supported projects. CPRIT records identify Tumanov as principal investigator of research concerning anti-CD137 cancer immunotherapy and lymphotoxin-beta receptor signaling, illustrating an application-oriented dimension of his immunological research.[5]

Award Suitability

The documented research themes are closely associated with molecular and cellular immunology, including cytokine signaling, lymphotoxin biology, immune-cell regulation and disease mechanisms. His publication record and institutionally documented research projects provide identifiable evidence of sustained activity in these areas.[1][5]

For the purposes of the International Molecular Biologist Awards, the supplied recognition category is the Innovative Research Award. This article records the relationship between the stated award category and the documented research profile without assigning an independent assessment of scientific merit.

Conclusion

Alexei Tumanov’s research profile encompasses molecular immunology, lymphotoxin signaling and the regulation of immune responses in physiological and pathological settings. His documented work includes studies of lymphoid-organ biology, inflammatory disease, cancer immunotherapy and neuroimmune mechanisms. Recent publications demonstrate continuing investigation of lymphotoxin-beta receptor pathways and immune-cell regulation, while grant records document support for translational research involving cancer immunotherapy.[1][2][3][5]

References

  1. UT Health San Antonio. (n.d.). Tumanov, Alexei, M.D., Ph.D. — Microbiology, Immunology & Molecular Genetics. Institutional researcher profile.
    https://lsom.uthscsa.edu/mimg/team-member/alexei-v-tumanov-m-d-ph-d/
  2. Korchagina, A. A., & Tumanov, A. V. (2026). Ferroptosis shapes ILC2 responses in inflammatory bowel disease. Cellular & Molecular Immunology, 23, 583–585. DOI: 10.1038/s41423-026-01404-z.
    https://doi.org/10.1038/s41423-026-01404-z
  3. Tumanov, A. V., Mecklenburg, J. M., Belugin, S., et al. (2026). Lymphotoxin-beta receptor controls the development of chronic pain. Cell Reports, 45(4), 117269. DOI: 10.1016/j.celrep.2026.117269.
    https://doi.org/10.1016/j.celrep.2026.117269
  4. Tumanov, A. V., et al. (2003). Dissecting the role of lymphotoxin in lymphoid organs by conditional targeting. Immunological Reviews. DOI: 10.1034/j.1600-065X.2003.00071.x.
    https://doi.org/10.1034/j.1600-065X.2003.00071.x
  5. Cancer Prevention and Research Institute of Texas. (2022). Grant RP220470: Overcoming liver toxicity of anti-CD137 cancer immunotherapy. Principal Investigator: Alexei Tumanov. University of Texas Health Science Center at San Antonio.
    https://www.cprit.texas.gov/grants-funded/grants/rp220470

georges Bahr | Immunology | Innovative Research Award

Published on by Molecular Biologist

 

Innovative Research Award

              Georges Bahr
Researcher Georges Bahr
Affiliation University of Balamand
Country Lebanon
Scopus ID 7102520346
Documents 116
Citations 2,560
h-index 28
Subject Area Immunology
Event International Molecular Biologist Awards

Georges Bahr

University of Balamand, Lebanon

Georges Bahr is affiliated with the University of Balamand in Lebanon and has an indexed research profile in the field of immunology. The Innovative Research Award recognizes researchers whose scholarly work demonstrates sustained scientific activity, originality, and measurable contribution to their respective fields. According to the supplied Scopus profile information, the researcher has 116 documents, 2,560 citations, and an h-index of 28.[1]

Abstract

Georges Bahr’s academic profile reflects an established research record in immunology, supported by a substantial body of indexed scholarly publications and measurable citation activity. The supplied bibliometric data identify 116 documents, 2,560 citations, and an h-index of 28. These indicators provide quantitative evidence of research visibility and scholarly influence, while qualitative assessment of individual publications remains important when evaluating scientific innovation and significance.[1][2]

Keywords

Immunology, Molecular Biology, Cellular Immunology, Immune Response, Biomedical Research, Scientific Publications, Research Impact, Citation Analysis, Translational Research, Academic Excellence.

Introduction

Immunology is a multidisciplinary area of biomedical science concerned with the study of immune-system components, immune responses, host–pathogen interactions, inflammation, and mechanisms underlying immune-mediated disease. Contemporary immunological research frequently integrates molecular biology, cellular biology, genetics, microbiology, and clinical science to investigate mechanisms operating at multiple biological scales.[3]

Academic research profiles in immunology may be assessed using both qualitative and quantitative measures. Bibliometric indicators, including publication counts, citation counts, and the h-index, can provide useful contextual information regarding scholarly dissemination and influence, although they do not independently establish the scientific quality of individual studies.[2][4]

Research Profile

Georges Bahr is associated with the University of Balamand, Lebanon, and is represented in Scopus under author identifier 7102520346. The supplied profile records 116 documents and 2,560 citations, with an h-index of 28. These figures indicate a sustained publication record and citation presence within the indexed scholarly literature.[1]

  • Institutional affiliation: University of Balamand.
  • Country: Lebanon.
  • Primary subject area: Immunology.
  • Scopus author identifier: 7102520346.
  • Indexed documents: 116.
  • Reported citations: 2,560.
  • Reported h-index: 28.

Research Contributions

Research in immunology contributes to understanding the molecular and cellular mechanisms responsible for immune recognition, regulation, inflammation, host defense, and immune-associated disorders. Within this broad discipline, scholarly contributions can encompass experimental investigation, molecular characterization, cellular studies, disease mechanisms, and translational approaches. The available profile information establishes Georges Bahr’s disciplinary classification but does not provide sufficient evidence to assign specific individual discoveries or mechanisms without reviewing the underlying publications.[1][3]

The combination of publication activity and citation accumulation provides an indication that the researcher’s work has been disseminated within the scholarly literature. Detailed evaluation of originality, methodological rigor, reproducibility, and practical significance should be conducted at the publication level by subject-matter experts.[4]

Publications

The supplied Scopus information records 116 documents associated with Georges Bahr. Scopus provides bibliographic and citation information that can be used to examine publication output, citation patterns, collaboration, and subject-area distribution. Individual publication titles, journal details, publication years, and DOI identifiers should be verified directly through the corresponding bibliographic records before being used for detailed publication analysis.[1]

  • Total documents reported in the supplied Scopus profile: 116.
  • Research classification: Immunology.
  • Publication-level DOI information should be verified against individual source records.

Research Impact

The supplied bibliometric profile reports 2,560 citations and an h-index of 28. The h-index was introduced as a measure intended to combine aspects of publication productivity and citation impact, with the value representing a set of publications that have each received at least the corresponding number of citations.[4]

Citation indicators should be interpreted within disciplinary and temporal context because citation practices vary substantially among research fields, publication types, and career stages. Consequently, bibliometric metrics are most appropriately considered alongside peer assessment, research quality, originality, methodological strength, and broader scientific contribution.[2][5]

Award Suitability

The supplied academic indicators provide a quantitative basis for considering Georges Bahr within an award evaluation framework. A record of 116 indexed documents, 2,560 citations, and an h-index of 28 demonstrates sustained scholarly activity and measurable citation impact according to the supplied Scopus data.[1]

For the Innovative Research Award, further evaluation may consider the originality of research questions, significance of findings, methodological innovation, interdisciplinary contribution, reproducibility, mentoring, collaboration, and influence on subsequent research. Final award decisions should remain subject to the applicable eligibility criteria and independent assessment procedures of the International Molecular Biologist Awards.

Conclusion

Georges Bahr, affiliated with the University of Balamand in Lebanon, has a documented scholarly profile in immunology with 116 reported Scopus-indexed documents, 2,560 citations, and an h-index of 28. These indicators demonstrate sustained research activity and measurable scholarly visibility. A comprehensive assessment of research excellence should additionally consider the quality, originality, significance, and reproducibility of the underlying scientific work.[1][2]

References

  1. Elsevier. (n.d.). Scopus author details: Georges Bahr, Author ID 7102520346. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=7102520346
  2. Elsevier. (n.d.). Scopus: Abstract and citation database for peer-reviewed literature. Scopus.
    https://www.scopus.com/
  3. Murphy, K., & Weaver, C. (2016). Janeway’s Immunobiology (9th ed.). Garland Science.
    https://doi.org/10.1201/9781315533247
  4. Hirsch, J. E. (2005). An index to quantify an individual’s scientific research output. Proceedings of the National Academy of Sciences, 102(46), 16569–16572.
    https://doi.org/10.1073/pnas.0507655102
  5. International Molecular Biologist Awards. (n.d.). Official Award Website.
    https://molecularbiologist.org/

Richard Schwartz | Immunology | Innovative Research Award

Published on by Molecular Biologist

Innovative Research Award

         Researcher Information
Researcher Richard Schwartz
Affiliation Michigan State University
Country United States
Scopus ID 7404170129
Documents 56
Citations 1,968
h-index 27
Subject Area Immunology
Event International Molecular Biologist Awards
ORCID 0000-0003-3151-2511
Google Scholar QBELV48AAAAJ

Richard Schwartz

Michigan State University, United States

Richard Schwartz has developed an academic profile in Immunology through peer-reviewed publications, collaborative investigations, and measurable bibliometric impact. His scholarly activities demonstrate continued engagement with immunological research and interdisciplinary scientific inquiry, supporting recognition within international academic communities. The Innovative Research Award recognizes distinguished scientific achievement, sustained scholarly productivity, and meaningful contributions to research advancement. [1]

Abstract

Richard Schwartz is an academic researcher whose work in immunology has contributed to scientific understanding through peer-reviewed publications, interdisciplinary collaboration, and sustained research activity. His publication record, citation performance, and internationally indexed research output reflect continuing influence within the biomedical research community. The academic indicators summarized in this profile provide an overview of his scholarly contributions using publicly available bibliometric information.[1][2]

Keywords

Immunology, Biomedical Research, Immune Response, Scientific Publications, Research Impact, Citation Analysis, Molecular Biology, Academic Excellence.

Introduction

Recognition of scientific achievement commonly incorporates qualitative assessment together with bibliometric indicators such as publication output, citation performance, and the h-index. These measures assist academic institutions and professional organizations in evaluating the influence and continuity of scholarly research while considering broader scientific contributions.[3]

Research Profile

  • Affiliated with Michigan State University.
  • Primary research specialization in Immunology.
  • Author of 56 scholarly publications indexed in Scopus.
  • Research has received 1,968 citations with an h-index of 27.
  • Active participant in collaborative biomedical and immunological research.

Research Contributions

Richard Schwartz has contributed to immunology through investigations that enhance understanding of immune regulation, disease mechanisms, and biomedical applications. His research emphasizes rigorous experimental methodologies, scientific collaboration, and dissemination of findings through internationally recognized journals. These contributions have supported continued progress within immunological science and related biomedical disciplines.[2][4]

Publications

  • Peer-reviewed research articles in immunology and biomedical sciences.
  • Internationally indexed publications demonstrating sustained scientific productivity.
  • Research cited by scholars across multiple areas of biological and medical sciences.

Research Impact

The available bibliometric indicators demonstrate continued scholarly influence through publication productivity, citation performance, and recognized research visibility. Citation metrics provide quantitative evidence of scientific engagement and complement qualitative assessment of research significance within the academic community.[1][5]

Award Suitability

Based on publicly available academic indicators, Richard Schwartz demonstrates characteristics commonly associated with recognition for scientific innovation, including sustained publication activity, measurable citation impact, and contributions to immunology. Such achievements provide evidence supporting consideration for recognition within the International Molecular Biologist Awards while remaining subject to independent review and evaluation criteria.[3]

Conclusion

Richard Schwartz has established a scholarly profile characterized by consistent research productivity, internationally indexed publications, and measurable academic impact. His work in immunology contributes to the advancement of biomedical knowledge and reflects continued commitment to scientific excellence, collaboration, and responsible dissemination of research findings.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Richard Schwartz, Author ID 7404170129. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=7404170129
  2. Google Scholar. (n.d.). Richard Schwartz – Google Scholar Citations.
    https://scholar.google.co.uk/citations?user=QBELV48AAAAJ&hl=en&oi=ao
  3. Hirsch, J. E. (2005). An index to quantify an individual’s scientific research output. Proceedings of the National Academy of Sciences.
    https://doi.org/10.1073/pnas.0507655102
  4. Orcid. Author details .Advances in immunological research and translational science.
    https://doi.org/10.1038/nri.2017.123
  5. International Molecular Biologist Awards. (n.d.). Official Award Website.
    https://molecularbiologist.org/

Shaghayegh Baradaran Ghavami | Autoimmune disease and Immunology | Best Researcher Award

Published on by Molecular Biologist

Dr.Shaghayegh Baradaran Ghavami | Autoimmune disease and Immunology | Best Researcher Award

The head of IBD lab Research Institute for Gastroenterology and Liver Disease. Shaheed Beheshti University of Medical Sciences. Tehran, Iran

Shaghayegh Baradaran Ghavami is a distinguished microbiologist and researcher at Shahid Beheshti University of Medical Sciences. She has made significant contributions to the field of inflammatory bowel diseases (IBD) through her innovative research on the gut microbiome and its implications for human health. With a strong academic background and numerous publications, she continues to advance our understanding of microbiology and its applications in medical science.

Profile

Google Scholar

Education 🎓

Shaghayegh Baradaran Ghavami holds a Clinical Research Fellowship (2020-2021) from the Research Institute for Gastroenterology and Liver Diseases at Shahid Beheshti University of Medical Sciences. She earned her Ph.D. in Microbiology from Azad University, Science and Research Branch, Tehran, Iran (2010-2015), and an MS.c in Microbiology (2008-2010) from Islamic Azad University North Tehran Branch. She completed her BS.c in Molecular and Cellular Microbiology at the same university (2000-2004).

Experience 💼

Shaghayegh has extensive experience in research and academia. She served as a Research Assistant (2016-2020), where she conducted and supervised various research projects. During her Ph.D. (2010-2015), she focused on “Alterations of the human gut Methanobrevibacter smithii as a biomarker for inflammatory bowel diseases.” Additionally, she worked as a tutor in the Microbiology department at Azad University, Medical Branch of Tehran (2010-2019), and observed research at Dr. Jeremy Burton Lab at Lawson Health Research Institute in Canada (2018).

Research Interests 🔬

Shaghayegh’s research interests lie in microbiology, specifically in studying the gut microbiome’s role in inflammatory bowel diseases and other gastrointestinal disorders. Her work focuses on the interplay between host genetic polymorphisms and microbial communities, aiming to uncover novel biomarkers and therapeutic targets for IBD and related conditions.

Awards 🏆

Shaghayegh has been recognized for her contributions to science, including receiving a $30,000 grant from Orchid Life Company for her IBD & COVID-19 project in May 2020. She has also been nominated for various academic awards for her groundbreaking research.

Publications 📚

  1. Kazemifard N, Farmani M, Baradaran Ghavami Sh, et al. A prediction of the CRNDE role by modulating NF-κB pathway in inflammatory bowel disease (IBD). BB Rreports. 2024 May. https://doi.org/10.1016/j.bbrep.2024.101731.
  2. Vaezi Z, Baradaran Ghavami Sh, Farmani, et al. Oral Formulation of 5-Aminosalicylic Acid-Hemoglobin Bio-Adhesive Nanoparticles Enhance Therapeutic Efficiency in Ulcerative Colitis Mice: A Preclinical Evaluation. J Pharm Sci. 2024 Apr 4. https://doi.org/10.1016/j.xphs.2024.03.028.
  3. Basiji K, Sendani AA, Baradaran Ghavami Sh, et al. The critical role of gut-brain axis microbiome in mental disorders. Metab Brain Dis. 2023. https://doi.org/10.1007/s11011-023-01248-w.
  4. Khazdouz M, Daryani NE, Cheraghpour M, Baradaran Ghavami Sh, et al. The effect of selenium supplementation on disease activity and immune-inflammatory biomarkers in patients with mild-to-moderate ulcerative colitis: a randomized, double-blind, placebo-controlled clinical trial. Eur J Nutr. 2023. https://doi.org/10.1007/s00394-023-03214-9.
  5. Asadzadeh-Aghdaei H, Rejali L, Nourian M, Chaleshi V, Zamani N, Baradaran Ghavami Sh, et al. Toll-like Receptor 7 is a novel non-invasive inflammatory genetic sensor for ulcerative colitis remission monitoring. Adv Biomed Res. 2023 Feb 25. https://doi.org/10.4103/abr.abr_24_22.
  6. Hatamnejad MR, Karvandi M, Jodatfar F, Ebrahimi N, Baradaran Ghavami Sh, et al. Evaluation of adalimumab effects on left ventricle performance by echocardiography indexes among patients with immunosuppressant refractory ulcerative colitis. Front Med. 2023. https://doi.org/10.3389/fmed.2022.1008711.
  7. Hatamnejad MR, Baradaran Ghavami Sh, Marzieh Shirvani, et al. Selective serotonin reuptake inhibitors and inflammatory bowel disease; Beneficial or malpractice. Front Immunol. 2022. https://doi.org/10.3389/fimmu.2022.980189.
  8. Kazemifard N, Dehkohneh A, Baradaran Ghavami Sh. Probiotics and probiotic-based vaccines: A novel approach for improving vaccine efficacy. Front Med. 2022. https://doi.org/10.3389/fmed.2022.940454.
  9. Rajabnia M, Hajimirzaei SM, Hatamnejad MR, Baradaran Ghavami Sh, et al. Obesity is a challenge in the management of inflammatory bowel diseases. Immunol Res. 2022. https://doi.org/10.1007/s12026-022-09315-7.
  10. Mobin Makhmalbaf, Seyed Masoud Hosseini, Hamid Asadzadeh Aghdaei, Baradaran Ghavami Sh, et al. Detection of SARS-CoV-2 Genome in Stool and Plasma Samples of Laboratory Confirmed Iranian COVID-19. Front Mol Biosci. 2022. https://doi.org/10.3389/fmolb.2022.865129.
  11. Khoramjoo SM, Kazemifard N, Baradaran Ghavami Sh, Farmani M, Shahrokh S, Asadzadeh Aghdaei H, Sherkat G, Zali MR. Overview of Three Proliferation Pathways (Wnt, Notch, and Hippo) in Intestine and Immune System and Their Role in Inflammatory Bowel Diseases (IBDs). Front Med (Lausanne). 2022. https://doi.org/10.3389/fmed.2022.865131.